Detalhe da pesquisa
1.
Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer.
Breast Cancer Res Treat
; 198(1): 67-74, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36624321
2.
Uptake of bone-modifying agents in patients with HER2+ metastatic breast cancer with bone metastases - prospective data from a multi-site Australian registry.
Intern Med J
; 52(10): 1707-1716, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34002929
3.
Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer.
Breast Cancer Res Treat
; 184(1): 87-95, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32779037
4.
Increasing complexity in oncology phase I clinical trials.
Invest New Drugs
; 37(3): 519-523, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30443782
5.
Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer.
Int J Mol Sci
; 20(12)2019 Jun 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-31238530
6.
Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy.
Cancer Sci
; 109(11): 3383-3392, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30230653
7.
Advanced Cancer Patients' Understanding and Perceptions of Phase I Clinical Trials.
Cancer Invest
; 33(10): 490-5, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26460889
8.
How well informed is the informed consent for cancer clinical trials?
Clin Trials
; 11(6): 686-8, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25135910
9.
A Phase 1 Proof of Concept Study Evaluating the Addition of an LSD1 Inhibitor to Nab-Paclitaxel in Advanced or Metastatic Breast Cancer (EPI-PRIMED).
Front Oncol
; 12: 862427, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35719960
10.
Real-World Outcomes in Patients With Brain Metastases Secondary to HER2-Positive Breast Cancer: An Australian Multi-centre Registry-based Study.
Clin Breast Cancer
; 22(7): e764-e772, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35941066
11.
Selective Targeting of Protein Kinase C (PKC)-θ Nuclear Translocation Reduces Mesenchymal Gene Signatures and Reinvigorates Dysfunctional CD8+ T Cells in Immunotherapy-Resistant and Metastatic Cancers.
Cancers (Basel)
; 14(6)2022 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35326747
12.
Simple and effective bacterial-based intratumoral cancer immunotherapy.
J Immunother Cancer
; 9(9)2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34531247
13.
Association between tyrosine-kinase inhibitor induced hypertension and treatment outcomes in metastatic renal cancer.
Cancer Rep (Hoboken)
; 3(5): e1275, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32767664
14.
Targeting Nuclear LSD1 to Reprogram Cancer Cells and Reinvigorate Exhausted T Cells via a Novel LSD1-EOMES Switch.
Front Immunol
; 11: 1228, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32612611
15.
Cervical cancer: is the wall crumbling?
Cancer
; 120(22): 3585-6, 2014 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25044122
16.
Eligibility criteria for phase I clinical trials: tight vs loose?
Cancer Chemother Pharmacol
; 83(5): 999-1002, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30809701
17.
A comparison of the quality of informed consent for phase I oncology trials over a 30-year period.
Cancer Chemother Pharmacol
; 82(5): 907-910, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30151620
18.
A phase I pharmacokinetic and pharmacodynamic study of GTI-2040 in combination with gemcitabine in patients with solid tumors.
Cancer Chemother Pharmacol
; 82(3): 533-539, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30022224
19.
Role of immunotherapy in bladder cancer: past, present and future.
Cancer Chemother Pharmacol
; 81(4): 629-645, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29368051
20.
Single institutional series of neuroendocrine tumors managed in the Australian Capital Territory.
Asia Pac J Clin Oncol
; 12(1): e133-40, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24164683